Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Hayato Nagasawa"'
Autor:
Wataru Hirose, Masayoshi Harigai, Koichi Amano, Toshihiko Hidaka, Kenji Itoh, Kazutoshi Aoki, Masahiro Nakashima, Hayato Nagasawa, Yukiko Komano, Toshihiro Nanki, for the TOF-ABT Study Group
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-12 (2021)
Abstract Objectives The aim of this study was to compare the clinical effectiveness of tofacitinib and abatacept and clarify the impact of the HLA-DRB1 shared epitope (SE) on responses to these treatments in patients with rheumatoid arthritis (RA). M
Externí odkaz:
https://doaj.org/article/8072e3ec640d40be86ca5bbb0e68cc83
Autor:
Yasuo Niki, Tsutomu Takeuchi, Masanori Nakayama, Hayato Nagasawa, Takahiko Kurasawa, Harumoto Yamada, Yoshiaki Toyama, Takeshi Miyamoto
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e37447 (2012)
PURPOSE: With the current use of biologics in rheumatoid arthritis (RA), there is a need to monitor ongoing structural joint damage due to the dissociation of articular cartilage damage from disease activity of RA. This study longitudinally analyzed
Externí odkaz:
https://doaj.org/article/8246686b84e24a3486016a8931b1ba07
Autor:
Wataru Hirose, Masayoshi Harigai, Koichi Amano, Toshihiko Hidaka, Kenji Itoh, Kazutoshi Aoki, Masahiro Nakashima, Hayato Nagasawa, Yukiko Komano, Toshihiro Nanki
Publikováno v:
Rheumatology Advances in Practice. 6
Objective We compared the 52-week effectiveness and safety of tofacitinib (TOF) and abatacept (ABT) in patients with RA in a real-world setting and investigated a role of human leucocyte antigens (HLA)-DRB1 shared epitope (SE) in the effectiveness. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::528fb73964719d1162b535fc76025533
https://doi.org/10.1093/rap/rkac090
https://doi.org/10.1093/rap/rkac090
Autor:
Masaru Kato, Isao Yokota, Hitomi Kobayashi-Haraoka, Yuko Kaneko, Masayuki Inoo, Hidekata Yasuoka, Nobuyuki Miyasaka, Eiichi Tanaka, Masayuki Miyata, Shintaro Hirata, Hisashi Yamanaka, Yoshiya Tanaka, Hayato Nagasawa, Tatsuya Atsumi, Kazuhiko Yamamoto, Tsutomu Takeuchi, Yohko Murakawa, Koichi Amano
Publikováno v:
Modern Rheumatology. 30:442-449
Objectives: To identify predictive factors for remission by tocilizumab monotherapy in rheumatoid arthritis (RA) patients.Methods: This is a post hoc analysis of the SURPRISE study, a 2-year random...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bc60a1ab588698b1d8b74478cb93183
https://doi.org/10.1080/14397595.2019.1621026
https://doi.org/10.1080/14397595.2019.1621026
Autor:
Hayato Nagasawa, Eiko Nishi, A. Shibata, Yusuke Okada, Koichi Amano, Hirofumi Takei, Tsuneo Kondo, Ayumi Okuyama, K. Chino, Ryota Sakai, Takahiko Kurasawa
Publikováno v:
Clinical Rheumatology. 36:2383-2392
The purpose of this study is to report the efficacy and safety of a combination of tocilizumab (TCZ) and high-dose corticosteroid (CS) in two patients with microscopic polyangiitis (MPA) and review the published current clinical evidence on TCZ in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3d27dfbf835d2b5e149de749c0c1560
https://doi.org/10.1007/s10067-017-3752-0
https://doi.org/10.1007/s10067-017-3752-0
Autor:
Yusuke Okada, Eiko Nishi, Koji Nishimura, A. Shibata, Ayumi Okuyama, Hayato Nagasawa, Hirofumi Takei, Kouichi Amano, Takahiko Kurasawa, Tsuneo Kondo, Ryota Sakai, K. Chino
Publikováno v:
Lupus. 27:273-282
Background Pulsed cyclophosphamide or mycophenolate mofetil for lupus nephritis has limited efficacy. We previously reported a case of mixed-class IV + V lupus nephritis successfully treated with cyclophosphamide and tacrolimus. This study assessed t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3f378cae2389575901d6509a667fcb3
https://doi.org/10.1177/0961203317719148
https://doi.org/10.1177/0961203317719148
Autor:
Koichi Amano, Satoshi Kubo, Kanako Iwata, Hayato Nagasawa, Yoshiya Tanaka, Eiichi Suematsu, Shuji Nagano, Shigeto Tohma, Kunihiro Yamaoka
Publikováno v:
Rheumatology. 56:1293-1301
Objective To determine whether tofacitinib can be discontinued in patients with RA who achieve low disease activity (LDA). Methods RA patients with LDA after tofacitinib treatment in a phase III and long-term extension study were enrolled in this mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e377198c44216cb4ce7a12e8f22862ce
https://doi.org/10.1093/rheumatology/kex068
https://doi.org/10.1093/rheumatology/kex068
Autor:
Tsutomu Takeuchi, Isao Yokota, Koichi Amano, Nobuyuki Miyasaka, Hayato Nagasawa, Tatsuya Atsumi, Yuko Kaneko, Yoshiya Tanaka, Kazuhiko Yamamoto, Masayuki Miyata, Masayuki Inoo, Masaru Kato, Hitomi Kobayashi-Haraoka, Hidekata Yasuoka, Shintaro Hirata, Hisashi Yamanaka, Yohko Murakawa, Eiichi Tanaka
Publikováno v:
Poster Presentations.
Background: Interleukin (IL)-6 pathway inhibitors are suggested by European League Against Rheumatism recommendations to have some advantages in rheumatoid arthritis (RA) patients who are not suitable to use methotrexate as comedication compared with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88ad062217e54f2bec0bfec4d2365bc9
https://doi.org/10.1136/annrheumdis-2019-eular.505
https://doi.org/10.1136/annrheumdis-2019-eular.505
Autor:
Koichi Amano, Yuko Kaneko, Hayato Nagasawa, Tsutomu Takeuchi, Tatsuya Atsumi, Yohko Murakawa, Masayuki Miyata, Hitomi Kobayashi-Haraoka, Eiichi Tanaka, Yoshiya Tanaka, Kazuhiko Yamamoto, Nobuyuki Miyasaka, Masayuki Inoo, Shintaro Hirata, Hisashi Yamanaka, Hidekata Yasuoka
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveTo compare the efficacy and safety between tocilizumab added to methotrexate and tocilizumab switched from methotrexate in patients with active rheumatoid arthritis (RA).MethodsThis is a 2-year randomised, controlled study. RA patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18f8a7579e3657842069b0392a03a357
http://ir.lib.shimane-u.ac.jp/53465
http://ir.lib.shimane-u.ac.jp/53465
Autor:
Yasunari Miyazaki, Hayato Yamazaki, Yasushi Kawaguchi, Yasuhiko Nishioka, Kazuyoshi Saito, Makoto Dohi, Ryoko Sakai, Hideto Kameda, Masako Hara, Kaori Watanabe, Yuko Kaneko, Ryuji Koike, Masayoshi Harigai, Nobuyuki Miyasaka, Hayato Nagasawa, Shigeto Tohma, Yoshinari Takasaki, Toshihiro Nanki, Shintaro Hirata, Shinsuke Yasuda, Michi Tanaka
Publikováno v:
Modern Rheumatology. 25:609-614
Connective tissue disease-associated interstitial pneumonia (CTD-IP) significantly affects the mortality of patients with CTD. The purpose of the present study is to identify causes and risk factors for death during hospitalization for immunosuppress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8621ecf638cf4387eef895570f76277c
https://doi.org/10.3109/14397595.2014.980384
https://doi.org/10.3109/14397595.2014.980384